Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/15/2025

Systemic Sclerosis Treatment

Introduction to Treatment Guidelines

  • The European League Against Rheumatism (EULAR) recommends against the use of golimumab or any TNF inhibitors in their treatment algorithms for any manifestation of systemic sclerosis, due to a lack of supporting evidence 1, 2, 3
  • EULAR guidelines are based on systematic literature reviews and expert consensus, with a focus on evidence-based pharmacological treatment of SSc-specific organ involvement 4, 1

Vascular Manifestations

  • For patients with vascular manifestations, such as Raynaud's, digital ulcers, or pulmonary arterial hypertension (PAH), EULAR recommends the use of calcium channel blockers, PDE5 inhibitors, prostacyclins, or endothelin receptor antagonists as first-line treatment 1, 4
  • Bosentan is recommended for the prevention of new digital ulcers in patients with scleroderma, according to EULAR 4, 5
  • Fluoxetine may be considered for SSc-related Raynaud's phenomenon, according to EULAR and the European Society of Rheumatology 4

Musculoskeletal Involvement

  • For patients with musculoskeletal involvement, methotrexate is the only agent specifically recommended by EULAR, with a Level of Evidence 2b and Strength of Recommendation D 1, 6
  • Methotrexate (15 mg/week) is recommended as first-line therapy for extensive/diffuse skin involvement by EULAR 2, 6
  • Limited scleroderma has less extensive skin involvement and typically doesn't require aggressive systemic immunosuppression for skin manifestations alone, with topical corticosteroids recommended for limited lesions and UVA1 phototherapy for circumscribed lesions, as suggested by EULAR 6, 5

Pulmonary Involvement

  • Cyclophosphamide is recommended for severe cases of interstitial lung disease (ILD) in patients with scleroderma, with first-line therapy being mycophenolate mofetil (500-1000 mg/m²) and nintedanib considered for progressive fibrotic ILD, as suggested by EULAR and the American Thoracic Society 2, 4, 6, 7
  • Initial therapy for pulmonary hypertension includes combination therapy with PDE-5 inhibitors and endothelin receptor antagonists, with additional therapy with prostacyclin analogues and riociguat as newer options, as recommended by the European Society of Cardiology and the American Heart Association 4, 6, 5

Gastrointestinal Involvement

  • Proton pump inhibitors are recommended for the treatment of gastroesophageal reflux disease (GERD) in patients with scleroderma, with prokinetic agents and rotating antibiotics used for motility disorders and bacterial overgrowth, and nutritional support recommended for malnutrition, as suggested by EULAR and the European Society of Gastroenterology 2, 6, 5

Renal Involvement

  • High-dose ACE inhibitors are recommended as first-line therapy for the treatment of scleroderma renal crisis, with glucocorticoids avoided or used at low doses, as suggested by EULAR and the European Society of Nephrology 2, 4, 6

Diagnostic Evaluation and Monitoring

  • The following diagnostic evaluation is recommended for scleroderma:
Test Description
Clinical evaluation Documentation of cutaneous architectural changes
Serological tests Complete panel of antibodies (e.g. anti-centromere, anti-topoisomerase I, anti-RNA polymerase III)
Pulmonary function tests Assessment of lung function
HRCT of the chest Evaluation of lung involvement
Echocardiography Detection of pulmonary hypertension
Capillaroscopy Evaluation of microvasculature

4, 6

  • Regular monitoring is crucial for early detection of organ involvement, including pulmonary function tests, HRCT of the chest, echocardiography, and capillaroscopy, as recommended by EULAR and the American College of Rheumatology 5, 8, 6
  • Complete joint examination, including temporomandibular joint, and ophthalmological follow-up, including uveitis screening, are essential for monitoring disease progression and managing complications, as suggested by EULAR 6

Patient Education and Support

  • Patient education about the disease and its management, avoidance of cold exposure, and psychological support are recommended due to the impact on quality of life, as suggested by EULAR, the British Association of Dermatologists, and the American College of Rheumatology 6, 5, 9